About Red Cell Therapeutics™

At Rubius Therapeutics^®, we are creating red blood cells and turning them into potential medicines, called Red Cell Therapeutics.

Rubius Therapeutics has two distinct investigational approaches to treat cancer – first, through broad immune system stimulation, and second, through a more direct approach, called antigen-specific stimulation, which is designed to instruct the immune system to target specific types of cancer.

Broad Immune System Activation for the Treatment of Cancer

Red Cell Therapeutics for the treatment of cancer are designed to have combinations of cancer-fighting molecules on the cell surface that have the potential to activate and expand the body’s own immune system to attack cancer cells.

Antigen-Specific Immune System Stimulation

Red Cell Therapeutics are engineered to express cancer-fighting molecules and specific proteins, known as antigens, on the cell’s surface. These antigens that are bound to the surface of the cell have the potential to selectively instruct only those cells of the immune system that have the ability to recognize and attack the tumor.

Frequently Asked Questions About Red Cell Therapeutics

What are Red Cell Therapeutics?

Rubius Therapeutics’ Red Cell Therapeutics are red blood cells that have been genetically engineered into investigational cellular therapies for the potential treatment of cancer and autoimmune diseases.

How are Red Cell Therapeutics made?

Red blood cells are continuously replenished by the body from precursor cells in the bone marrow to maintain healthy levels in circulation.
Rubius Therapeutics uses these precursor cells to create its Red Cell Therapeutics.
These precursor cells are collected from healthy O-negative blood donors.

To turn these precursor cells into investigational cellular therapies, Rubius Therapeutics uses a process called genetic engineering to insert an extra gene or genes encoding therapeutic proteins into the cell.
The precursor cells are then placed into cell culturing tanks, where they grow and turn into red blood cells.
During the culturing process, the cells lose their nucleus, leaving the therapeutic protein in or on the surface of the red blood cell.

How are Red Cell Therapeutics given to a patient?

Red Cell Therapeutics are administered via infusion into a vein.

In what treatment setting is a patient given Red Cell Therapeutics (e.g. doctor’s office, infusion center)?

Red Cell Therapeutics will be given at the clinical trial center.

How do I know that the donor’s cells used to make Red Cell Therapeutics are safe?

The cell supply that Rubius Therapeutics uses to create Red Cell Therapeutics is rigorously tested for safety and quality and comes from certified centers that meet federal safety standards.
Donors are screened for infectious diseases and donor blood is tested for infectious agents, similar to other blood-based products.

Sign up to learn more about Red Cell Therapeutics™

and receive updates about clinical trials that might be available in your area for yourself or a loved one.

Please correct the following errors and submit the form again.

Please enter your first name.

Please enter your last name.

Please enter a valid email address.

Please enter your 10-digit phone number.

Please enter your 5-digit zip code.

Disease

Please select at least one disease.

I AGREE TO ALLOW RUBIUS THERAPEUTICS TO STORE AND PROCESS MY PERSONAL DATA SO THAT I MAY RECEIVE COMMUNICATIONS FROM RUBIUS THERAPEUTICS. In order to provide you the content requested, we need to store and process the personal data you provided above. You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy. You can unsubscribe from these communications by following the ‘unsubscribe’ link in any email we send, or email us at clinicaltrials@rubiustx.com and ask us to remove you from our communications.

Thank you

We will contact you about your submission